• Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 3,180.74%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.64
▲ +0.02 (3.23%)

This chart shows the closing price for BLRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioLineRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLRX

Analyst Price Target is $21.00
▲ +3,180.74% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BioLineRx in the last 3 months. The average price target is $21.00, with a high forecast of $21.00 and a low forecast of $21.00. The average price target represents a 3,180.74% upside from the last price of $0.64.

This chart shows the closing price for BLRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in BioLineRx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$21.00N/A
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$21.00Low
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$21.00Low
11/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$21.00Low
9/15/2023HC WainwrightBoost TargetBuy ➝ Buy$19.00 ➝ $21.00Low
8/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$19.00Low
3/22/2023HC WainwrightReiterated RatingBuyLow
8/22/2022OppenheimerLower Target$6.00Low
5/4/2021Maxim GroupBoost TargetBuy$5.00 ➝ $10.00High
3/1/2021HC WainwrightLower TargetBuy$22.00 ➝ $19.00N/A
2/23/2021HC WainwrightReiterated RatingBuy$22.00 ➝ $19.00High
12/16/2020HC WainwrightBoost TargetBuy$18.00 ➝ $22.00High
8/7/2020Maxim GroupReiterated RatingBuyLow
7/20/2020HC WainwrightReiterated RatingBuyHigh
3/13/2020OppenheimerLower Target$26.00 ➝ $11.00High
3/12/2020HC WainwrightReiterated RatingBuy$18.00Low
12/13/2019HC WainwrightReiterated RatingBuyHigh
12/6/2019HC WainwrightReiterated RatingBuyHigh
8/7/2019HC WainwrightReiterated RatingNeutralLow
7/22/2019Maxim GroupReiterated RatingBuy$10.00Medium
5/14/2019HC WainwrightSet TargetBuy$3.00Low
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/21/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/21/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/20/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/19/2024
  • 8 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/18/2024

Current Sentiment

  • 8 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
BioLineRx logo
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.
Read More

Today's Range

Now: $0.64
Low: $0.61
High: $0.66

50 Day Range

MA: $1.07
Low: $0.62
High: $1.38

52 Week Range

Now: $0.64
Low: $0.61
High: $2.53

Volume

305,735 shs

Average Volume

397,767 shs

Market Capitalization

$51.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Frequently Asked Questions

What sell-side analysts currently cover shares of BioLineRx?

The following Wall Street research analysts have issued reports on BioLineRx in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for BLRX.

What is the current price target for BioLineRx?

1 Wall Street analysts have set twelve-month price targets for BioLineRx in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 3,180.7%. HC Wainwright has the highest price target set, predicting BLRX will reach $21.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $21.00 for BioLineRx in the next year.
View the latest price targets for BLRX.

What is the current consensus analyst rating for BioLineRx?

BioLineRx currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLRX will outperform the market and that investors should add to their positions of BioLineRx.
View the latest ratings for BLRX.

What other companies compete with BioLineRx?

How do I contact BioLineRx's investor relations team?

BioLineRx's physical mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company's listed phone number is (728) 642-9100 and its investor relations email address is [email protected]. The official website for BioLineRx is www.biolinerx.com. Learn More about contacing BioLineRx investor relations.